Introduction
Approximately 15% of couples in Europe are deemed infertile. Male-factor infertility accounts for just under 50% of the underlying cause, meaning that in Europe alone, 18 million men are unable to have a child through natural conception [1] .
Developments in assisted reproductive techniques (ART) have transformed the management of male factor infertility and the advent of intracytoplasmic sperm injection (ICSI) in 1993 was a landmark in the management of the infertile male. While this has been an undoubted success, it has led to a shift away from understanding and correcting the potential reversible causes of male factor infertility, to one that simply overcomes it with ART.
The aetiology of male infertility can broadly be divided into impaired spermatogenesis, or impaired sperm transport within the genital tract. The most challenging of these is male infertility attributable to azoospermia, which affects approximately 10-15% of infertile men (2.7 million men in Europe).
In recent years, the investigation and treatment of men in the UK presenting with infertility has been variable, depending on the patient's geographical location and access to male fertility specialists. In April 2017 NHS England (NHSE) published a commissioning policy (B14X07/01) relating to surgical sperm retrieval (SSR) for infertile men. In this document it is proposed that commissioning for SSR should be limited to men '..diagnosed with azoospermia by a urologist with an interest in male infertility problems in a specialized urology centre with established links with an HFEA [Human Fertilisation and Embryology Authority]-licensed fertility centre' or men who are due to undergo '. . .surgery or chemotherapy that would result in infertility, and who cannot produce sufficient sperm for storage'. Cases commissioned for SSR must have '..a reasonable likelihood of successful retrieval of motile sperm' and 'confirmed funding for subsequent stages of the pathway (cryopreservation and/or IVF treatment)' [2] . Whilst the document focuses on patients requiring SSR, it is important to remember that there are potential reversible causes for azoospermia, which are often overlooked. These should be investigated at the outset and patients informed of the potential medical or surgical interventions available and the likely outcomes with regard to live birth rates. The aim is to try and restore natural fertility wherever possible, rather than to resort to ART as a first-line treatment option.
The NHSE document defines a patient pathway where the primary care physician refers infertile men, after two confirmatory azoospermic semen analyses, to a urologist with an interest in male infertility in a specialist urology centre [2] . A detailed assessment of the patient, including a physical examination of the scrotal contents, hormone analyses, genetic screening and a review of the semen characteristics, allows the urologist to diagnose accurately the underlying cause of azoospermia. Judicious use of imaging (TRUS, testicular ultrasonography or MRI) may be useful in selected cases to identify the underlying cause, or level of obstruction to sperm transport. After this assessment, it should then be possible to diagnose the condition as either obstructive azoospermia (OA) or non-obstructive azoospermia (NOA) (Figs 1 and 2 ).
The NHSE policy also states that patients should be treated as 'part of a specialist fertility MDT [multidisciplinary team] that includes urologists, a reproductive medicine physician and the scientific team'. Ideally, both partners should be seen together in a combined clinic, with the urologist focusing on the male partner. This provides the couple with a coherent plan and clear expectations for their fertility treatment.
Management of Men with Obstructive Azoospermia
In~40% of cases, azoospermia is attributable to a structural, or 'functional', obstruction within the reproductive tract. The obstruction can be located at any level, from the efferent tubules at the epididymal level to the external urethral meatus, although the areas amenable to reconstruction are often at the level of the epididymis, vas or ejaculatory ducts.
Vasal or epididymal obstruction can be successfully managed using microsurgical reconstructive surgery. The ability to offer epididymovasostomy is essential for those with proximal vasal obstruction not amenable to vasovasostomy or epididymal obstruction. Using a combination of either vasovasotomy or epididymovasostomy where necessary, a pregnancy rate of 43% has been reported, even in patients who have had a vasectomy >15 years ago [3] . Previous cost-benefit analyses have shown that the cost per delivery is significantly lower in the vasectomy reversal group than in the ART group, and the need for ovarian stimulation and egg collection is also avoided.
Ejaculatory duct obstruction is rare, but is one of the few surgically reversible causes of obstruction within the male reproductive tract and can be managed by performing a transurethral resection of the ejaculatory ducts (TURED). The reported patency rates after TURED are 65-95%, although the pregnancy rate is lower, at 20-42%.
In men where endoscopic or microsurgical reconstruction is not possible, or is unsuccessful, SSR is still likely to be successful using one of the following techniques: percutaneous epididymal sperm aspiration (PESA), testicular sperm aspiration (TESA) or conventional testicular sperm extraction (TESE). A meta-analysis of successful SSR rates in OA has reported retrieval rates of 80-100% (PESA), 98-100% (large-bore TESA), and 100% (TESE) [4] .
Management of Men with Non-obstructive Azoospermia
Non-obstructive azoospermia accounts for~60% of all cases of azoospermia, and remains the most challenging scenario in male-factor infertility. After initial investigations, any reversible cause should be diagnosed and treated. For example, men with hypogonadotrophic hypogonadism do not always require an SSR as sperm can often be retrieved from the ejaculate following a period of treatment using recombinant FSH and LH stimulation.
Significance of Varicoceles in Male Infertility
Varicoceles have been an area of controversy for many years, especially after a flawed meta-analysis by Evers and Collins, published in 2003 [5] . A sub-analysis of the original data to include only those with a clinically significant varicocele and infertility resulted in a significant improvement in pregnancy rates after varicocele correction [6] . Despite this, most centres in the UK still do not offer intervention for varicoceles unless they are associated with scrotal pain or discomfort.
There are a number of proposed mechanisms in which a varicocele may affect fertility, including scrotal temperature changes, effects on hormones, direct effects on spermatogenesis, and increased DNA fragmentation. Published meta-analyses have shown that correction of a varicocele can lead to significant improvements in semen characteristics, such as sperm concentrations and sperm motility. Randomized controlled trials have also shown that treatment of clinically significant varicoceles can improve the chance of a spontaneous pregnancy (odds ratio 3.04; numbers needed to treat 5.27) in oligozoospermic men.
In men with NOA and clinically significant varicoceles, treatment can lead to sperm appearing in the ejaculate in up to one in three men. Even in those who remain azoospermic, SSR after varicocele repair has a more than doubled chance of subsequent successful sperm retrieval.
Surgical Sperm Retrieval Techniques: MicroTESE
The primary option in men with irreversible NOA is SSR. Of all the currently available SSR techniques, a meta-analysis has shown that microTESE almost doubles the chance of a successful SSR compared with conventional TESE (weighted means 54% vs 33%) [7] . MicroTESE can also be successful in men with previous failed conventional TESE or TESA procedures. When one considers the significantly lower complication rates of microTESE compared with conventional there is histological evidence of sperm on the testicular biopsy, but no sperm found at the initial operation (only one further microTESE is funded).
Men with NOA who have an AZFa or AZFb Y chromosome deletion, or OA after vasectomy, or uncorrected undescended testes will not be funded for SSR under the new commissioning guidelines. Diagnostic biopsies being performed purely for a histological diagnosis will also not be funded unless they are performed with a simultaneous SSR.
Conclusion
Male-factor infertility is common, but with the widespread availability of ICSI, men previously deemed infertile can now father their own biological offspring. A full assessment and review of men by a urologist, as part of the fertility team, can identify the reversible causes of azoospermia prior to men and their partners committing to ART. Difficult NOA scenarios including men with AZFc Y deletions, Klinefelters syndrome or those with a failed previous conventional TESE can still be offered SSR in the form of microTESE. The recent NHSE policy offers guidance on commissioning SSR services, including the use of microTESE for men with azoospermia, and explicitly states that this should only be undertaken by surgeons with the appropriate training in scrotal surgery. The increasing number of trained urologists now offering microTESE throughout the UK, combined with the published guidance from the NHSE, should allow men diagnosed with azoospermia to seek specialist investigations and treatment without the previous challenges and geographical variation in accessibility to treatment for male infertility.
